Quick Answer
Quoin Pharmaceuticals, Ltd. reported Cash and Equivalents of $3.82 million for fiscal year 2025.
Quoin Pharmaceuticals, Ltd. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $3.82M | +5.4% |
| 2024 | $3.62M | +50.9% |
| 2023 | $2.40M | -16.1% |
| 2022 | $2.86M | -61.8% |
| 2021 | $7.48M | +2210.7% |
| 2020 | $323.8K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.83M | -41.3% | +9.7% |
| June 30, 2025 | $1.67M | -41.4% | -56.3% |
| March 31, 2025 | $3.82M | +108.5% | +5.5% |
| December 31, 2024 | $3.62M | +50.9% | +16.3% |
| September 30, 2024 | $3.12M | -1.5% | +9.5% |
| June 30, 2024 | $2.85M | -40.2% | +55.2% |
| March 31, 2024 | $1.83M | -45.6% | -23.6% |
| December 31, 2023 | $2.40M | -16.1% | -24.1% |
- Quoin Pharmaceuticals, Ltd. showed an increase of +5.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Quoin Pharmaceuticals, Ltd.’s cash and equivalents has grown by 1079.0% (from $323.8 thousand to $3.82 million).
- The most recent figure is from Quoin Pharmaceuticals, Ltd.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: